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                   GENERAL INTR 0D UCTION
   Oral drug delivery has been known for decades as the most widely utilized route of
administration among all the routes that have been explored for the systemic delivery of
drugs. However, when orally administered, drugs were subjected to extensive
metabolism in the liver, termed as the hepatic first-pass metabolism [1]. The
consequence of hepatic first-pass metabolism induces the low bioavailability, not
reaching to sufficient levels of drug in plasma for therapy.
   The nasal drug delivery offers many advantages that include the avoidance of the
hepatic first-pass metabolism, rapid absorption due to a highly permeable tissue and
ease of administration. Currently, two classes of nasally delivered therapeutics are on
the market. The first class includes local anti-inflammatory. The second one
includes a few peptide drugs such as buserelin, desmopressin and calcitonin.
   The nasal cavity has a large surface area for absorption of.drugs due to the fact that
the nasal cavity is covered with numerous microvilli and the presence of turbinate
structures. Furthermore, the subepithelial layer is highly vascularized with the
additional benefit of the venous blood passing directly into the systemic circulation
thereby avoiding the first-pass metabolism.
Airway epithelium in the nose consists of four cell types. These are nonciliated
columnar cells, goblet cells, basal cells, and ciliated columnar cells (Figure 1). The
goblet cells, together with the nasal glands in the respiratory pathways, produce the
mucous secretion. The mucosal surface is covered by a layer of secretions, which
contain mucous glycoproteins, imunoglobulins, albumin, lysozome, and other
substances. Basically, there are two transport pathways potentially involved drug
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               Figure 1. The structure ofnasal epithelium
               I. nonciliated columnar cell with microvilli,
               II. goblet cell, III. basal cell, IV. ciliated coiumnar cell
permeation across epithelial membranes; the paracellular and the transcellular pathway
(Figure 2). Mainly, the hydrophilic drug passed between cells (paracellular pathway),
and this pathway was restricted by tight junctions located between mucosal membranes.
The hydrophilic drug permeability is dependent on the molecular weight [2] although
the molecules with less than 1,OOO Da are relatively permeated across mucosal
membrane [3,4]. On the other hand, transcellular pathway means that hydrophobic
drug traverses inside cells. Large hydrophilic drugs such as peptide and protein are not
easily absorbed by the nasal route. Most peptide and protein show the low
bioavailabilities when administered nasally. The main reasons for such a low degree
of absorption ofthese molecules has reasonably been suggested to be their hydrophilic
nature, their large molecular size and physiological factors such as enzymatic
degradation of the molecules in the nasal cavity and their movement away from the
y.'
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          Figure 2. Drug transport pathway across mucosa membrane
          (I) paracellular pathway, (II) transcellular pathway
absorption site by the mucociliary clearance mechanism. To improve the low
absorption and to control the drug concentration in plasma, two main strategies have
been used; modification of permeability across the nasal membrane by the use of
absorption enhancers, and a mechanical approach using bioadhesive gel system and
various dosage forms.
                                            '
   Budesonide used in Chapter I is steroidal drug for asthna, allergic and seasonal
rhinitis (Figure 3). Considering the effective therapeutic regimens for budesonide,
pharmaceutical dosage form of sustained release type will be desired for increase of the
bioavailability, keeping the effective therapeutic level for a long time, and avoiding the
unexpected side effects. Therefore, I developed pH-sensitive and mucoadhesive
polymer system in which the polymer works as membrane-disruptors and adhesive
agents at the pH ofnasal mucosa (Figure 3), and thereby the system can continuously
3
Grafted copolymer ofPMAA and PEG in a 1:1 ratio
          9H, FH,
cH, - F           CH2 -C
              -CNNHOoc
       m=O
             [Hilll
             1
          -l
             H
  Neutral condition
              O Drug
     o
  o
n
PEG
PMAA
pH 4.8
Budesonide
`ptli,.
  c-ow
11MLtHtMCXs
 i""iio-Cuc-Cng
                          Åq =Åro
                                            o
              06
                         Characteristics of P(MAA-g-EG)
        Figure 3. Chemical structures of P(MAA-g-EG) copolymer and budesonide, and
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release the drug from the polymer.
   In Chal)ter ll, to increase drug absorption, I discussed novel enhancers, B-sitosterol
P-D-glucoside (Sit-G), the main component of soybean-derived sterol glucoside (SG)
and P-sitosterol (Sit), the main component of soybean-derived sterol (SS). Sit has the
similar structure with cholesterol as shown in Figure 4, which is mainly contained in
plants. In the pharmaceutical field, these compounds were used as the excipients and
emulsifiers. Furthermore, it is known that Sit inhibits the uptake of cholesterol
showing higher affinity to biological membrane than cholesterol [5,6], and induces the
inhibition of proliferation, and apoptosis of tumor cells [7-9]. On the other hand, SG
and Sit-G are potential carrier for selective liver targeting due to accumulation into liver
[10,11]. Furthermore, Sit-G has the antihyperglycemic effect as the pharmacological
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     Figure 4. Chemical structure and components of soybean-derived sterylglucoside (SG)
     P-Sitosterol P-D-glucoside (Sit-G); R=C2H, (49.9 O/o)
     Campesterol B-D-glucoside; R=CH3 (29.1 O/o)
     Stigmasterol P-D-glucoside; R=C2Hs and A22 (13.8 O/o)
     Brassicasterol B-D-glucoside; R :CH3 and A22 (7.2 O/o)
effect due to a stimulation of insulin secretion from pancreatic P-cells [12]. Recently,
the absorption enhancing effect of Sit-G and Sit for nasal delivery was reported without
inducing the irritation to nasal mucosa [13,14]. However, the enhancing effect by the
enhancers was attempted to only insulin, and the mechanisms of enhancer action are
still unclear. Fully understanding these mechanism is of importance for therapeutic
applications.
   To increase the bioavailability by the increase of residence time and interaction of
the formulation on the nasal mucosae, various dosage forms such as powders, emulsions,
liposomes and nanoparticles (NP) have been used. In Chapter Ill, NP based on Sit or
Sit-G was developed to improve their low solubility and to avoid incomplete dispersion
ln water.
   In Chapter I, the release of the drug from mucoadhesive and pH-sensitive
copolymers in nasal delivery was discussed. In Chapter ll, the enhancing effect by Sit
5
and Sit-G, and their mechanisms were investigated, focusing on the lipid bilayer barrier,
as well as transcellular/paracellular pathways. In Chapter III, the enhancing effects of
the NP dosage forms based on Sit or Sit-G were discussed for nasal absorption.
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ChapterI
Retease Pro77tes ofBudesonidefrom Mucoadhesive,
   pH-Sensitive Copolymersfor Nasal Deliver v
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1. Introduction
   To provide the sustained drug absorption, bioadhesive polymers have been used.
Highly swellable, anionic hydrogels that exhibit mucoadhesive behavior could be
extremely usefu1 in nasal delivery applications (Table 1) [15]. Such gels would swell
significantly when in contact with the mucosa (pH of almost 7 in nasal mucus) and
release the drug in a continuous fashion while adhering to the mucosa. At this point, a
pH-sensitive, hydrogel based poly(methacrylic acid) (PMAA) grafted with
poly(ethylene glycol) (PEG) ((P(MAA-g-EG)) was selected. Because of the unique
chemical structure, the gel swells in neutral or basic conditions due to the ionization of
the pendant acid groups and deswells in acidic media owing to the interpolymer
complexation between PEG and PMAA [16] as shown in Figure 3. Additionally, the
gel strongly adheres to the mucosa when it was in the highly swollen conformation [17].
                   Table 1. Bioadhesive polymers enhancer
                   used for nasal mucosa
                     Arginate
                     Carbopol
                     Carboxymethylcellulose
                     Chitosan
                     Hydroxyethylcellulose (HEC)
                     Hydroxypropylcellulose (HPC)
                     Hydroxypropylmethylcellulose (HPMC)
                     Methylcellulose (MC)
                     Pulronic F127
                     Starch
                     Tamarind gum
                     Xanthan gum
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   The drug selected for this study was budesonide. Budesonide is a derivative of
16-ct-hydroxypredonisolone, and is reported to have low bioavailability (10.7 O/o)
following oral administration [18]. Nasal administration ofbudesonide is used for the
treatment of allergic and seasonal rhinitis, and is also effective for astlma. Therefore,
controlled systemic circulation of the drug is required to improve the therapeutic
efflciency.
   In Chapter I, I investigated the loading ofthe drug into the polymeric microparticles,
the in vitro release kinetics •and the pharmacokinetics following intranasal
administration of the drug-containing gels in rabbits.
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2. Experimental Section
2-1. Materials
   Budesonide with a mixture oftwo epimers was purchased from Sigma Chemical Co.
(St. Louis, MO). P(MAA-g-EG) microparticles containing a 1:1 molar ratio ofPMAA
and PEG chains of 1,1OO molecular weight were prepared as described previously [17].
The polymers used contained a nominal molecular weight between crosslinking of
6,OOO. The structures of the budesonide and the copolymers are shown in Figure 3.
All other reagents were ofanalytical grade or best.
2-2. Drug loading in polymer and analysis ofdrug
   Budesonide (3 mg) was dissolved in 10 mL ethanol or ethanol solutions ofvarious
concentration; 50 O/o ethanol solutions adjusted with trisaminomethane-HCI buffer
(Tris-buffer) to pH 7.19 and 25 O/o ethanol solutions adjusted with Tris-buffer or NaOH
to pH 7.23 and 7.30, respectively. Initially dry copolymer microparticles were
dispersed in the drug solutions and stirred at a constant rate for one day. The weight
ratio ofdrug to polymer in the initial solution was varied from 1:1 to 1:3. At specified
time points, 100 pL samples were withdrawn from the solutions using filtered syringes
(Ishikawa Manufactory Co.). The budesonide concentration in each sample was
measured by HPLC. N-propyl-p-hydroxybenzoic acid-methanol solution was used as
an intrastandard. The HPLC system (LC-10 AS, Shimadzu Co. Ltd.) was equipped
with a UV detector (SPD-10AV, Shimadzu Co. Ltd.) at 254 nm. The mobile phase,
consisting of a waterlethanol mixture (57143 by volume), was eluted through a
reverse-phase column (3.9 x 150 mm (in vitro) and 4.6 x 150 mm (in vivo)) packed with
Nova Pak C18 (Waters, Milford, USA) at rate ofO.5 mLlmin at room temperature.
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   Following drug loading, the solutions were filtered using 1 pm filter paper and an
equal volume of the first fluid (JP XIII) was added to deswell the drug-loaded particles.
These P(MAA-g-EG) hydrogels containing budesonide were dried in vacuo for 3 days
and stored at 4 OC prior to use in further studies [19].
2-3. Release studies ofdrugfrom budesonide-polymer
   Budesonide-containing microparticles (3 mg) were dispersed in 30 mL of a 25 e/o
ethanol solution adjusted with NaOH to pH 7.30 and stirred at a constant rate. At
regular intervals, 200 pL samples were withdrawn using a filtered syringe. After each
sample was removed, an equal volume of the ethanol solution was returned to the
solution. Budesonide concentration in each sample was measured by HPLC.
2-4. Preparation ofbudesonide dosageforms
   Budesonide solution for intravenous administration was prepared by dissolving the
drug in an ethanol solution and diluting the solution with saline so that the final
concentration of ethanol was about 50 O/o, A mixture of 2:1 (weight) of
budesonide:lactose was dissolved in 30 O/o ethanol solution and freeze-dried.
Budesonide-containing copolymers (budesonide:copolymer = 1:1, weight) could be
administered alone to achieve the desired dosage because low drug content in polymer
and the limited volume of nasal cavity. Therefore, the powder dosage form which
consisted of a 1:1 (weight) physical mixture budesonideflactose and
budesonide-containing polymer was used. The samples for nasal administration were
passed through a 200-mesh sieve to yield particles with a radius of 75 ptm or less and
were stored at 4 OC until use.
                                   Il
2-5. Animal experiment
   Male Japanese rabbits weighing between 2.5 and 3 kg were obtained from Saitama
Experimental Supply (Japan) and used through all experiments. For the animals
receiving intravenous budesonide, about 1 mL of budesonide solution containing 2
mglkg body weight dose was injected in the rabbits. The nasal administration was
carried out by the following methods. A polyethylene tube with inner diameter ofO.97
mm, outer diameter of 1.27 mm and length 10 cm (Netsuke Seisakusyo Co. Ltd.) was
attached to the top ofa syringe and inserted in the nasal cavity about 2.0 cm from nostril.
Nasal administration was limited to one side of a nasal cavity in each experiment.
Powder dosage form was loaded into the syringe and administered through the tube into
the site ofthe nasal cavity using the procedure previously described [20].
   The powder dosage form of budesonide was administered to rabbits at a dose of 2
mg budesonidelkg. After each time point, 200 pL blood samples were collected
serially from the ear vein of the animals. The plasma samples were separated by
centrifugation at 13,OOO rpm for 3 min, and then the protein was extracted by addition
of 1 mL isopropanolldichlromethane to 100 pL plasma samples. The organic acid
phase was taken in a test tube and evaporated by gentling heating in a N2 stream. The
residue was dissolved in 200 pL of the mobile phase described above. The samples
were injected into HPLC system to determine the budesonide concentration.
   The experimental procedures described above were performed according to the rules
set by the Committee on Ethics in the Care and Use of Laboratory Animal in Hoshi
University.
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2-6. Analysis ofpharmacokinetic data
   The total area under budesonide concentration-curve (AUC) from time O to 8 hr was
estimated from the sum of successive trapezoids between each data point.
Bioavailability (F) was defined on the basis of AUC according to the following
equatlon:
                      AUCnasallDosenasal
                   F= Å~100 Eq. 1.
                       AUCj.v.IDosei,v.
where AUCnasai and AUCi... represent AUC after nasal administration and intravenous
administration of 2 mg budesonide/kg in rabbits, respectively.
   The mean residence time (MRT hr) were determined using MULTI [21].
                            '
2-7. Data analysis
   For group comparison, the one-way layout analysis of variance (ANOVA) with
duplication was applied. Significant differences in the mean values were evaluated by
Student's unpaired t-test. Ap value ofless than O.05 was considered significant.
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3. Results and Discussion
   Budesonide is a poorly soluble drug in water. On the other side, P(MAA-g-EG)
swells to a high degree in water when the pH is greater than 4.8 [16]. In order to
optimize the loading conditions for budesonide in this polymer, the uptake and release
behavior ofthe drug were examined in ethanollwater solutions ofvarious concentrations
at physiological pH.
3-1. Drug loading eXI7ciency and release study
   The uptake profile ofbudesonide into P(MAA-g-EG) in ethanol solutions is shown
in Figure 5 at an initial drug/polymer ratio of3 in the solution. Less than 10 O/o of the
budesonide were incorporated into the polymer in pure ethanol and 50 O/o ethanol
solution adjusted with Tris-buffer. However, in the solutions with decreased amounts
of ethanol, 25 O/o ethanol solutions adjusted with NaOH and Tris-buffer, nearly 50 O/o of
budesonide partitioned into the polymer (Figure 5). The uptake profiles for both
solutions were nearly identical.
   The difference in the uptake behavior of the polymer in the different solutions can
be attributed to the pH-dependent swelling behavior of the P(MAA-g-EG) hydrogels.
The polymer networks swell due to electrostatic repulsions between dissociated
carboxyl groups of PMAA under neutral or basic conditions in media with high
dielectric constants like water [16]. The swelling behavior of these gels is reduced
when the degree of ionization of the PMAA is reduced in solutions with low dielectric
constants as in the case of solutions containing high concentrations of ethanol [161.
The uptake ofdrug in the polymers was very low in the 50 O/o ethanol and pure ethanol
14
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 Figure 5. e/o Decrease of budesonide by uptake to polymer (wlw) in various ethanol
 aqueous solutions adjusted with NaOH and trisaminomethane-HCI buffer at the 1:3
 ratio of drug to polymer at 25 OC
 D: ethanol, A: 50 O/o ethanol aqueous solution adjusted with buffer at pH 7.19, O: 25 O/o
 ethanol aqueous solution adjusted with buffer at pH 7.23, e: 25 O/o ethanol aqueous
 solution with NaOH at pH 7,30)
solutions because the swelling of P(MAA-g-EG) was significantly inhibited and the
drug did not partition into the collapsed gel (Figure 5). However, in solutions with
less ethanol, the gels swelled to a greater degree and the drug was incorporated more
favorably into the highly swollen networks. Each ofthe solutions had pH values very
close to 7. Therefore, the uptake of hydrophobic drugs such as budesonide into
P(MAA-g-EG) was affected by the organic solvent concentration more than by the
solution pH.
   The initial budesonidelpolymer weight ratio in the solution also had an effect on the
degree of loading ofbudesonide in the polymer. The decrease of solution budesonide
concentration is shown in Figure 6 for different initial druglpolymer weight ratios in
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polymer increased with increasing drug concentration.
   Applying these drug-containing polymers for nasal delivery, it is desirable to have a
large concentration of drug within the polymer. Therefore, hydrogels for nasal
absorption studies were prepared in 25 O/o ethanol solutions with pH 7.30 and initial
drug:polymer weight ratios of3. After soaking the swelling copolymers for 24 hr in
the drug solutions, the microparticles were dried as described above.
   The release behavior of the budesonide-loaded microparticles is shown in Figure 7.
The release ratio, defined as the ratio of the amount released at any time (Mt) to total
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amount released after 8 hr (M.), is plotted as a function of time (Figure 7A). The
release ofbudesonide from budesonide-polymer showed rapid burst, where about 60 O/o
budesonide were released less than 30 min. For the remainder ofthe time, the release
behavior appeared to be followed by a classical Fickian mechanism. The type of
release behavior was evaluated by plotting the release ratio, (M/M.) , as a function of
the squared root of time (Figure 7B). After the initial burst, a linear relationship
between the release ratio and ti!2 was seen. This type ofprofile indicates that the release
behavior of budesonide from the gel was governed by an initial burst due to rapid gel
swelling followed by the diffusion ofdrug from the gels [22].
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Figure 7. Release profiles of budesonide from polymer micropanicles plotted
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Each value represents as means Å} S.D. (n= 3).
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3-2. Nasal administration ofbudesonide/polymer
   The plasma budesonide concentration profiles following intravenous and nasal
administration of budesonide solution and budesonidelpolymer are shown in Figure 8.
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Following nasal administration of the polymeric formulations, the peak plasma
concentration was reached at about 45 min, indicating an initial rapid release of
budesonide from the polymer and absorption of budesonide through the nasal mucosa.
After the initial burst, the concentration in plasma remained fairly constant for a
minimum of8 hr This indicates that the budesonide was continuously released from
the polymer due to diffusion. In comparison, following intravenous administration of
budesonide, the plasma concentration peaked immediately and decreased rapidly over
the next 4 hr At 5 hr following the intravenous administration, the plasma
concentration ofbudesonide had decreased to nearly undetectable levels.
   The pharmacokinetic parameters are shown in Table 2. The bioavailability of
budesonide following nasal administration of the polymeric formulation was 83.9 O/o.
The bioavailability was increased by durability of the drug concentration in plasma
despite budesonide has a short elimination half life (ti/2=29 min). Following
extravascular administration ofa drug powder dosage form, the observed total MRT is
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Figure 8. Plasma concentration profiles after intravenous administration of budesonide
solution and intranasal administration of budesonidelpolymer at a dose of 2 mg/kg
budesonide in rabbits
Each value represents as means Å} S.D. (n=4).
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Table 2. Pharmacokinetic parameters ofbudesonide following intravenous and nasal administration of
budesonide solution and budesonidelpolymer, respectively, at a dose of 2 mglkg budesonide in
 AUCo.s
(pg'hr•mL-i)
MRT
(hr)
VRT
(hF)
F a)
(o/o)
Intravenous
  Budesonide solution b)
Intranasal
  Budesonidelpolymer C)
1.24
1.04
1.69
3.95
3.34
6.00
1OO
83.9
  MRT is the mean residence time, and VRT is variance ofresidence time.
  Each value represents the mean.
  tit2= 29 min
  a) F from O to 8 hr
  b) Budesonide was dissolved in 500/o ethanol aqueous solution.
   c) The ratio ofbudesonide to polymer is 1:1.
the sum of the MRT in the body, i.e., the mean absorption time, the mean dissolution
time and the mean release time. The permeation of budesonide might be enhanced by
the adhesion of P(MAA-g-EG) to the mucus since the MRT values after nasal
administration ofbudesonidelpolymer increased. The total mean dissolution time and
the mean release time can be determined 2.26 hr from the difference between the MRT
values, after nasal and i.v bolus dose given on separate occasions (Table 2). It was
reported that bioavailability of drug with the bioadhesive compound such as chitosan
[23], and carbopol, i.e., poly (acrylic acid) [24] was increased by bioadhesive action of
polymer to the mucus.
   Typically, polymers containing carboxylic-acid groups adhere strongly to mucosa
due to hydrogen bond interactions in environments where the pH is less than 5, where
the carboxylic acid does not dissociate. In this case, the carboxylic acid groups were
ionized at pH of approximately 7, however, the strong mucoadhesive characteristics
were observed due to the interpenetration of the mobile PEG-grafts and PMAA
dangling chains. At this pH, P(MAA-g-EG) hydrogels are highly swollen and the
chains are relatively mobile. The mobile chains are able to penetrate the mucosa and
19
may be able to diffuse into the gels. This chain interpenetration serves as a physical
attaciment between the gels and the mucosa [17]. In terms of the release
characteristics and in vivo performance, the drug-containing polymer swelled rapidly
within 30 min and released the drug continuously for at least 8 hr. During this period,
the hydrogels adhered strongly to the nasal mucosa allowing for the high bioavailability
ofthe drug.
20
4. Conclusions
   The conditions of budesonide loading in a pH-sensitive and mucoadhesive polymer,
P(MAA-g-EG), were examined using various ethanol solutions. Ethanol was required
for drug solubilization but hindered hydrogel swelling in 50 O/o ethanol solutions at even
pH 7.2. The maximum loading efficiency of the drug in the polymer was obtained
using 25 O/o ethanol solutions at pH 7.3. The release from the drug loaded-polymers
was followed by a classical Fickian kinetics after the initial burst. This system was
evaluated using nasal absorption in rabbits to confirm whether these gels could
effectively deliver the drug in a similar fashion under physiological conditions, such as
nasal mucosa. Modulation ofthe gel swelling and mucoadhesiveness may prove to be
usefu1 in the controlled release of drug from pH-sensitive and adhesive polymer at the
surface ofthe nasal mucosa in vivo.
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Chapter II
Enhancing Effect of/3PSitosterot J6LD-Gtucoside and /3,Sitosterot
  on IntranasatAbsorption of Verapamit and FITC-Dextran
             4,400 at Powder Dosage Form
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1. Introduction
   To increase bioavailability ofdrug absorption, absorption enhancers such as bile salt
[25], cyclodextrin [26] and saponin are co-administered [27]. However, most of them
are haimfu1 to nasal epithelium and interfere with nasal mucociliary movement [28,29].
The clinical use of absorption enhancers is not available in Japan except for sodium
caprate. Therefore, the search for safe and effective absorption enhancers is an
important issue in the both of academia and industry.
   Recently, it was reported that SG and SS promoted insulin absorption through nasal
mucosae following intranasal administration of suspensions [13] and powder dosage
forms with SG [14]. No damages to nasal mucosa were evoked in successive
intranasal administration of SG for 5 days [14]. However, the enhancing mechanisms
of these compounds have not been clarified yet.
   In Chapter II, I examined the activity of these enhancers on nasal absorption of
verapamil and FITC-dextran 4,400 (FD-4) as model drugs, employing powder dosage
forms in rabbits. Intranasal administration of verapamil seems to be the suitable since
Table 3. Bioavailability ofverapamil and FD-4 through the various administered sites
op                  DoseAnimal Administrered route                      F rrmlation
                (rr1glcg) Enalmcer F (O/o) Ref
Verapami1 Dog oraiNasal
2.5
O.75
Solmion l3Å}3
36Å}7 [30]
Rat
Nasal 10 Soimion
1 O/o wlv Glycocholate
1 e/o wfv Taurocbolate
1 O/o w!v EDTA
1 O/o wlv C1O
22 Å} 1.3
11.7Å}2.0
1I5Å}2.0
10.1Å}1.9
13.0Å}3.0
[41
FD--4 Pulmonary 5 Sohaion
1 O/o w!v Glycocbolate
1 O/o wlv EDTA
1 O/o wlv C1O
72 Å} l.1
29.0 Å} 1.5
19.4 Å} 2.4
31.8Å}2.3
[31]
Rabbit Nasal 1
Microsphere
 (powder)
Lactose
Chrosan
Carbopol 934P
 9.1Å}3.8
12.6 Å} 4.5
32.7 Å} 13.2
[32]
Pig Buccal O.22 Solution
1O MM Sodium glycodeoxycbohte
1.8 Å} O.5
12.7 Å} 2.8
[33]
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this drug was subject to the extensive first-pass metabolism in the liver when
administered orally [30] (Table 3). Further enhancement of bioavailability of
verapamil wi11 be attained by the use ofenhancer. FD-4 is not therapeutic drug, but is
extensively used for evaluating the enhancer's activity because of its poor absorption in
various sites (Table 3).
   The second aim in this chapter is to elucidate the mode of action of SG and Sit-G.
Absorption enhancers are classified into two groups. The first one is the paracellular
type such as calcium chelator [31] and some compounds by which intracellular calcium
levels were increased [32,33]. Another one is transcellular type such as acylcarnitines
(Table 4) [37]. Sodium caprate (ClO) such as typical enhancer of paracellular type
induced the opening of tight junctions, which brought about the decrease of
transepithelial resistance (TEER) accompanied with increase of intracellular calcium
levels ([Ca2']i) [32,33]. On the other hand, enhancement mechanism of transcellular
type is attributed to the perturbation ofthe lipid bilayer. Change of [Ca2']i and TEER
values were monitored to estimate contribution ofparacellular pathway. At the same
time, the calcein leakage from liposomes as a model biomembrane was determined to
evaluate the role of transcellular pathway.
     Table 4. Classes of absorption enhancers
Enhancing route Absorption enhancers
Parapacellular route
Tianscelh]lar route
Chrosan
EDTA
Didecanoytpbosphatidyleboline
Glycryrrhetic ackl derivative
Unsatrurated fattty acld (C 1 O)
NO donor
Acyicamitine
Bile saft (sodium glycocbolate, sodium deoxycbolate)
MethYlated b-cyclodextrin
Saponin
Saturated fatty ackl (Oleic acld)
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2. Experimental Section
2-1. Materials
   SG (M.W. 573.32) and SS (M.W. 409.l7) were kindly supplied by Ryukakusan Co.
Ltd., (Tokyo, Japan). Sit was purchased from Tama Biochemical Co. Ltd. (Tokyo,
Japan). Sit-G (M.W. 578.84) was purchased from Essential Sterolin Products Ltd.
(Midrand, South Africa), and the purity of Sit-G was identified and determined to be
more than 96 O/o by i3C-NMR and thin layer chromatography (data not shown).
Verapamil hydrochloride, FD-4, cremophor EL, dimethyl sulphoxide (DMSO), and
dulbecco's phosphate-buffered saline (D-PBS) were purchased from Sigma Chemical
(St. Louis, MO). Oleic acid (M.W. 282.5), CIO and calcein were purchased from
Tokyo Kasei Kogyo (Tokyo, Japan). Fura PE3-AM was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). Egg phosphatidylcholine and cholesterol
were purchased from NOF Corp. (Tokyo, Japan). All other chemicals were obtained
from commercial sources and were of analytical reagent grade.
2-2. Preparation and administration ofdosage form
   The intranasal administration was described in Chapter L The FD-4 and verapamil
powder dosage forms were prepared by freeze-drying of the following solution
(verapamil: 75 mg verapamil, 225 mg lactose as control, SG, and Sit-G, FD-4; 100 mg
FD-4, 200 mg Iactose, Sit-G and Sit), and sieved through 200-mesh (particle size less
than 75 pm). The physical form of verapamil hydrochloride in all powder
formulations measured by X-ray diffraction apparatus (RINT 1400, Rigaku, Co. Tokyo)
was amorphous (data not shown). The 3 mg!kg of each powder dosage form of
verapamil and FD-4 was administered intranasally to Japanese male rabbits weighing
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2.5 - 3.0 kg at O.75 mg verapamillkg, and 1 mg FD-41kg by the previously reported
method [14]. The liquid dosage forms consist of two types such as suspension and
solution. The former was prepared by the sonication of 1 O/o wlv Sit or Sit-G sieved
through 200 mesh (75 pm) in saline since Sit and Sit-G are far solubility in water. The
latter was 1 O/o wlv CIO in saline. Aliquots of 200 pL each liquid dosage form were
administered via one nostril ofrabbits [38].
   For intravenous administration, verapamil hydrochloride and FD-4 (75 mg/mL and
15 mglmL in saline, respectively) was injected into the ear vein of rabbits at a dose of
O.75 mg verapamillkg, and 1 mg FD-41kg, respectively.
2-3. Determination ofverapamil and FD-4
   At each time point, blood sample was taken from ear vein, and then performed the
centrifugation at 13,OOO rpm for 3 min to obtain plasma.
   For the determination of verapamil in plasma, to 100 pL plasma samples, 1 mL
acetonitorile containing 140 nglmL butyl p-aminobenzoate was added as an internal
standard. Samples were mixed with a vortex mixer and centrifuged at 13,OOO rpm for
5 min. The organic solvent was evaporated at 50 OC under a gentle stream ofnitrogen
and the residues were dissolved in 200 yL of HPLC mobile phase. A 50 pL of this
solution was injected into an HPLC equipped with a fluorescent detector. The
instruments consisted of a Shimadzu LC 10AL liquid chromatography, SIL 10 A
autoinjector, CR-6A chromatopac, SCL 10A system controller and RF-10ALxL
fluorescent detector (Shimadzu, Kyoto). The detector setting was 275 nm for
excitation and 315 nm for emission [39]. A 3,9 x 300 mm column packed with Nova
Pak C18 (Waters, Milford, USA) was employed, The mobile phase was
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acetonitorile:O.13 M KH2P04 solution (40:60) pumped at a rate of 1.0 mLlmin [39].
   For the determination of FD-4 in plasma, 1OO pL plasma samples were added in 900
pL PBS and FD-4 concentration was measured by fluorescent spectrometer (Hitachi
F-401O, Tokyo) at an excitation wavelength of490 nm and emission wavelength of520
nm.
2-4. Analysis ofpharmacokinetic data
   The AUC values of verapamil and FD-4 from time O to infinity for verapamil, and 3
hr for FD-4were estimated from the sum successive trapezoids between each data point,
respectively. Bioavailability (F) was calculated according to Eq. 1 in Chapter I after
intravenous administration of O.75 mg verapamil!kg, and 1.0 mg FD-4!kg in rabbits,
respectively.
   The maximum concentration (Cmax), the time reached at Cmax (Tmax), and MRT
were determined using MULTI [21].
2-5. Measurement ofFD-4 and enhancers following administration ofpowder dosage
form in vitro
   After rabbits were sacrificed by injection of 85 mg!kg pentobarbital solution into the
ear vein, the nasal septum was removed and the excised nasal mucosa was mounted in
Franz-type diffusion cell with an available diffusion area of 1 cm2. The receiver side
was fi11ed with 16 mL Ringer's solution containing 125 mM NaCl, 5 mM KCI, 1.4 mM
CaC12, 1.2 mM KH2P04, and 11.0 mM D-glucose (pH 7.4) saturated with 95 O/o 02-5 O/o
C02 gas at 37 OC. Two mg of FD-4 powder dosage form with enhancers
(FD-4:enhancer = 1 :2 weight) was applied to the nasal mucosa using the same device as
27
in vivo study, and 1 mL sample was taken from the receiver side to measure the amount
of permeated FD-4 after 30 min. To remove the excess powder from the nasal
mucosae, the mucosae after permeation study were washed with Rjnger solution for
three times, and then the following procedures. To estimate FD-4 uptake into the nasal
mucosa, after extraction of lipids the mucosa was homogenized in 3 mL PBS, and FD-4
concentration in the sample was measured as described above. To estimate the uptake
of enhancers and the remaining amount of cholesterol at the surface and in the nasal
mucosa, the mucosa was washed with ethanol, and extracted using a 2:1 vlv mixture of
methanol and chloroform. Cholesterol, Sit and Sit-G were analyzed by HPLC. A 3.9
x 150 mm column packed with Nova Pak Cl8 (Waters, Milford, USA) was employed.
The mobile phase was methanol pumped at a flow rate of O.5 mLlmin.
2-6. Induction ofcalcein leakagefrom li osomes by enhancer
   Liposomes entrapped with calcein were prepared with 70 pmol egg
phosphatidylcholine and 30 pmol cholesterol according to the reverse-phase
evaporation method [40,41]. A liposome-1110 diluted PBS (1110 PBS) suspensions
was added to methanol-1/10 PBS in which the enhancer was dissolved and was
incubated at 37 OC for 60 min. The calcein leakage was assessed by fluorescence
spectrometry with excitation at 490 nm and emission at 520 nm [41]. Calcein leakage
was determined from the following equation:
                                     Ft - Fo
                   Calcein leakage (O/o) ==
                                           Å~100 Eq.2.
                                     2Fco -- Fo
where Fo and Ft are the fluorescence intensities of the calcein before and at time t after
incubation, respectively, and F. represents the florescence intensity when 100 ptL of
1O O/o Triton X-1OO was added to 1OO pL sample to completely collapse Iiposomes with
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encapsulating calcein.
2-7. Measurement oflCa2'7i
    Fura PE3-AM was loaded into nasal mucosa excised from nasal turbinate ofrabbit
[42]. Briefiy, fura PE3-AM was dissolved in DMSO and mixed with cremophor EL.
Nasal mucosa was exposed to 1 pM fura PE3-AM in the presence ofO.04 O/o cremophor
EL in the dark for 5 hr at room temperature. The tissue was rinsed with D-PBS with or
without 1 .4 mM Ca2' and placed in a bath containing 8 mL D-PBS with or without Ca2'
at 37 OC. The tissue was held vertically and equilibrated for 30 min. Then, DMSO
was added to a final concentration of about 1 O/o v/v. After 10 min, 2 mL of1 O/o
DMSO containing Sit-G (200 pM) was added to the bath followed by 50 pL CaC12
solution (200 mM) in saline, and finally 4 mL ionomycin solution (26 pM) was added at
each time to check fura PE3 adsorption, but inside the cells. [Ca2']i was measured as
the change in fluorescence intensity of fura PE3 bound to calcium with a
dual-wavelength fluorometric caicium analyzer, CAF 11O (Japan Spectroscopic, Tokyo,
Japan) at 340 nm and 380 nm for excitation and at 500 nm for emission [42].
2-8. Measurement ofTEER andFD-4permeability
   The excised nasal mucosa was mounted onto a tissue adapter in Ussing chamber
(CEZ-9100, Nihon Kohden, Tokyo). Each chamber was fi11ed with the 10 mL of
Ringer's solution. Temperature was kept constant at 37 OC by means ofwaterjackets
around the upper reservoirs. The apparent permeability coefficients (Papp expressed
as cm/sec) were calculated by the following equation;
              Papp=(deldt)1(CoxA) Eq.3
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where deldt is the fiux, Co is the initial concentration ofFD-4 on the mucosal side and
A is the surface area (O.673 cm2).
    For measurement of short-circuit current (Isc pA), the potential differences (PD)
were maintained at O mV with an automatic voltage clamp system. Isc and PD were
monitored at 10 min intervals for up to 120 min. TEER was calculated following
                     PD (mV)Ohn'S low, TEER(S:lt)" Isc(,LtA) Å~1000. TEER values are given as percentages of
the baseline TEER recorded prior to the addition of enhancers. The AUCTEER was the
calculated area under the TEER change curve from O to 120 min.
    One mL of 10 O/o w/v CIO, and Sit and Sit-G suspensions were added to the
mucosal side to give 1 O/o wlv as the final concentration ofenhancer. One mL samples
were taken at 10 min intervals for up to 120 min from the serosal side, and replaced
with an equal volume of fresh Ringer's solution. FD-4 concentration was determined
by the above method.
2-9. Confocal laser scanning microscopic visualization ofFD-4 transport
   After the permeation study, the nasal mucosa was fixed with Mildform@ 20N at
room temperature, and observed by confocal laser scanning microscopy (Radiance 2000,
Bio Rad Laboratories, Richmond, CA) linked to a Diaphot@ inverted microscope (Nikon,
Tokyo, Japan). Vertical and horizontal section images were taken with PlanAPO 60,
1.40 oil objective (Nikon), and FD-4 was excited at a wavelength of488 nm.
2-1O. Data analysis
   The data analysis was carried out by the method mentioned in Chapter L
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3. Results and Discussion
3-1. Effects ofenhancers on intranasal absorption ofverapamil and FD-4
   SG and SS are very low solubility in water (about 53 pg!mL) and they are used as
suspensions, or powder formulation for enhancer and excipient [14,38]. Figure 9
shows the plasma concentration profile of verapamil after intranasal administration of
verapamil powder dosage form with lactose, SG or Sit-G at a dose of O.75 mg
verapamillkg in rabbits. Cmax ofverapamil was reached within 7 min after intranasal
administration of each powder dosage form in rabbits. But, Cmax and F value after
intranasal administration of verapamil powder dosage form with SG significantly
increased compared with those with lactose as control. Moreover, Sit-G, the main
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Figure 9. Plasma concentration of verapamil following nasal
administration of verapamil powder with or without enhancers in
rabbits at a dose ofO.75 mg/kg
ÅqÅr: lactose, []:SG, O: Sit-G
Each value represents the mean Å} S.E. (n=5).
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Table 5. Pharmacokinetic parameters of verapamil following intravenous and intranasal
administration ofpowder dosage forms with enhancers at a dose of O.75 mg verapamillkg
in rabbits
Cmax (pgtml.) MRT a) (hri) F b) (o/.)
Intravenous
       Solution
Nasal
Powder dosageform C)
       Lactose
       SG
       Sit-G
1.02 Å} O.12
8i5Z6l8iO,l3,l li].., ?i8,g;8igg
O.396Å}O.023J" O.95Å}O.l3
1OO
zgs;]igl
90.7 Å} 9.8J
s***
 Each value represents the mean Å} S.E. (n= 5). "p Åq O.05, ""p Åq O.Ol, ""*p Åq O.OO1
 a) MRT is the mean residence time, that is the average time of a molecule residues in the body.
 b) F (Bioavailability from O to infinity, O/o) = AUC.,,.ilAUCi... X 1OO
 C) Drug:enhancer == 1:3 weight
component of SG, increased Cmax and F values up to 1.5 fold compared with that of
SG (Table 5). However, MRT values following intranasal administration with SG and
Sit-G were almost same as that following i.v. though bioadhesive polymer such as
chitosan prolonged MRT, which facilitated the drug absorption through mucosa [43].
This result suggests that SG and Sit-G induce significantly faster absorption of
verapamil from powder dosage form as i.v. injection.
   The influence of Sit and Sit-G on intranasal absorption of FD-4 was investigated by
the same method with verapamil. Figure 10 shows the plasma concentration profile of
FD-4 following intranasal administration ofpowder (A) and liquid (B) dosage forms at
a dose of 1 mg FD-41kg in rabbits. The pharmacokinetic parameters are listed in Table
6. Sit-G in the powder dosage form significantly facilitated the nasal absorption of
FD-4, i.e., Cmax, AUC, and F values compared with lactose. Tmax for powder dosage
forms was 42.5 min for lactose, 16.6 min for Sit and 24.1 for Sit-G, respectively. The
plasma concentration profiles for liquid dosage forms were different from those for
powder dosage forms. The AUC and F values in liquid dosage forms with Sit and
Sit-G were lower than those in powder dosage forms, consistent with the results for
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insulin [14,38], although CIO, which is used as an enhancer in nasal [42], colonic [44],
and rectal mucosa [45], showed the highest Cmax and F values in liquid dosage forms.
This difference in the enhancing effect between liquid and powder dosage form
suggested that the amount of enhancer in the liquid dosage form contacted with nasal
mucosa might be less compared with that in powder one because oftheir low solubility.
  In previous reports, SG and Sit-G facilitated the insulin absorption through the nasal
              (A) Powder dosage form (B) Liquid dosage form
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     Figure 10. Plasma concentration profile of FD-4 following intranasal
     administration of powder (A) and liquid dosage (B) forms without or with
     enhancers in rabbits at a dose of 1 mg FD-4!kg
     Åq]År: lactose, ": PBS, D: Sit, O: Sit-G
     Each value represents the mean Å} S.E. (n=4-6).
Table 6. Pharmacokinetic parameters of F[D-4 following intranasal administration of liquid and powder dosage forms
with enhancers at a dose of 1 mg FD-41kg in rabbits
Cmax
( niL) Tmx(miri)
MRT a) (hr) F b) (o/,)
Povvder dosageform
gi,Ii:...Se 8,Sili9I8,li]]** 1•ii.ii'ili]]**
Liguid dosage form
 SaJine (contrDD O.O13Å}O.O12 -
 10/, wlv CIO O.320Å}O.100 -
  10/o wlV Sit suspensions - '
  10/o w!v Sit-G suspensions - -
64.0Å} 8.4
63.8Å} 7.5
63.8Å} 4.6
69.1 Å} l8D
iiSi9ll2gÅí•].
iggi.i]].,
g14,lglg]"
L8Å}Ll
3.0 Å} O.9
Each value represents the mean Å} S.E. (n=5). 'p ÅqO.05, *' p ÅqO.O1
a) MRT is the mm residence tinre, that is the average time ofa mo}ecule residues in the body.
b) F (Bioavailability, e/o) = AUC.,,al!AUC, , X 100
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mucosa from insulin powder [14], and suspension dosage form [38]. In rabbits, the
intranasal administration of insulin powder formulation with 1 O/o SG resulted in 26.3 O/o
of F value and such powder formulations are superior in providing improved
enhancement of insulin transport across the nasal mucosa compared to their suspensions
[14,38]. Therefore, it shows that SG and Sit-G facilitate not only insulin but also
verapamil and •FD-4 absorption through nasal mucosa, indicating they act without
special interaction via an insulin exclusive absorption pathway. Furthermore, the
efficiency of Sit-G as an enhancer was significantly higher than SG (p Åq O.05), which
agrees with the previous results for insulin (Table 5).
   For the absorption enhancing mechanism of SG, Ando et al. [38] reported that SG
might affect the lipids in mucosal membrane since SG significantly increased the insulin
permeation through the artificial lipid membrane consisted of the mixture of n-caprylic
acid and lauryl alcohol (4:O.92) compared with SS. However, the detailed
enhancement mechanism is unclear. Therefore, I investigated the influence of
enhancers on paracellular and transcellular pathway.
3-2. Uptake ofFD-4 andenhancers after application ofFD-4powder
   Since Tmax values were near 30 min after intranasal administration, the effects of
enhancers on the permeated (A) and uptake amounts ofFD-4 (B) were examined in the
excised nasal mucosa 30 min after application of FD-4 powder (Figure 71). The
amount of FD-4 permeated through the nasal mucosa was significantly increased by
Sit-G and Sit compared with control (Figure 11A). Uptake amount ofFD-4 with Sit-G
significantly increased compared with control and Sit, although the permeated amount
of FD-4 with Sit-G was almost the same as that with Sit (17igure 11B). The uptake
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Figure 11. The permeated (A) and remaining (B) FD-4, and uptake of enhancer (C) in 1 cm2 excised nasal
mucosa 30 min after application of2 mg FD-4 powder dosage forms with enhancers (FD-4:enhancer == 1:2
weight) in Frantz diffusion cells
(a) and (b) in C represent the amount of enhancer in ethanol after washing the mucosal surface, and that in
nasal mucosa after extraction with methanollchloroform (1 12, vlv), respectively
Each value represents the mean Å} S.E. (n= 4). " p Åq O.05, "* p Åq O.O1
amount of enhancers and the amount of cholesterol remaining in the nasal mucosa after
application of each powder dosage form were measured. Sit amount in the nasal
mucosa was significantly higher than that on the surface, but Sit-G showed a greater
distribution on the nasal mucosal surface than Sit (Figure 11C). These differences may
be attributable to the hydrophobicity of the enhancers; Sit is more hydrophobic than
Sit-G. Also, the amount of remaining cholesterol was not significantly different
compared with control (data not shown). These findings were in a good agreement
with the observations that Sit-G did not cause the severe damage to nasal mucosa
following intranasal administration.
3-3. Calcein leakagefrom liposomes by enhancers
   To investigate the alteration of biological membranes by enhancers using liposomal
membrane as a model of biomembrane, calcein leakage from liposomes encapsulating
calcein was measured by the incubation with enhancer. Liposomes are often used for
biomembrane model [461. The effect of enhancer to mucosal membrane can be
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explained by the measurement and comparison ofcalcein leakage from liposomes.
   Calcein leakage from liposomes by the incubation with SG or Sit-G increased
dependently on the enhancer concentration and the incubated time, and these values in
SG and Sit-G at O.5 mM, significantly increased up to 13.2 O/o and 19.0 O/o, compared
with SS (1O.2 O/o) and Sit (6.6 O/o) for 60 min at 37 OC, respectively (Figure 12 and Table
b. On the other hand, calcein leakage in SS and Sit was saturated at above O.2 mM,
and appeared to stabilize the liposomes above 16 mol O/o (O.2 mM) within 30 min
(Figure 12 and Table 7).
        O O.1 O.2 O.3 O.4 O.5
                                            O O.1 O.2 O.3 O.4 O.5
et. 25 ;- SG tel. 25 Sit--G
rlfl is { T 'IS is
      O O.1 O.2 O.3 O.4 O.5 O O.1 O.2 O.3 O.4 O.5
       Concentration ofenhancer (mM) Concentration ofenhancer (mM)
Figure 12. Effect of enhancers on calcein Ieakage from Iiposomes with entrapped calcein in
methanol-1110 PBS (1:1) after incubation at 37 OC for 30 min (open symbol) or 60 min (closed
symbol)
Total lipid concentration was 1 .238 pmollmL.
Hatched line indicates the solubility ofeach enhancer in methanol-111O PBS (1 :1).
Each value represents the mean Å} S.D. (n=6).
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Table 7. The effect of various enhancers on calcein leakage from
liposomes with entrapped calcein after incubation at 37 OC for 60 min
Enhancer (mM) Calcein leakage (O/o)
O.05 02 O.5
Oleic acrd
ss
sit
SG
Sit-G
    o
3.1 Å} 2.7
    o
2.1 Å} 2.1
O.4 Å} O.4
    o
8.0 Å} 2.2
6.5 Å} 02
7.6 Å} 3.3
7.2 Å} 2.8
 5.7 Å} 3.4
10.2 Å} 1.7
igl2lg•;•]* ;1]
**
 ***
***
***
 Each value represents the mean Å} S.D. (n=3-6). '"p Åq O.O1, """p Åq O.OO1.
 Lipid concentration in methanol and PBS (1 : 1) was 1.238 pmollmL.
 SG, Sit-G, SS, and Sit were solubilized in methanol-1110 PBS (1:1), and oleic acid was
 solubilized in methanol-111O PBS (1:1).
  Incorporation of Sit into liposomes results in close packing in phospholipid layer
compared with cholesterol [47], since Sit increases the order parameter of liposomes
calculated from fluorescent anisotropy data at 37 OC [48]. This phenomenon was
consistent with in vivo data that Sit decreases the membrane fiuidity of cells in
keratinocytes at 37 OC. Based on these findings, the absorption enhancement by Sit
may not be dependent on transcellular pathway since the incorporated Sit made the
liposomal membrane rigid.
   In contrast, Sit-G may have opposite efifect to that of Sit. As described above, SG
promoted the insulin permeation through an artificial membrane modified with lipid but
Sit did not [38]. Moreover, Muramatsu et al. [47], and Qi et al. [41], reported that the
destabilizing effect of SS or SG on liposomes was greater in the order of SS Åq
cholesterol Åq SG, because SS was closely packed in phospholipid layer, but the glucose
group of SG disturbs the optimal packing state. The difference in enhancing efficiency
for SG and Sit-G may be due to the characteristic of the sterol side-chain and its role in
determining sterol-sterol and sterol-phospholipid interactions as in analogues of
cholesterol having different side-chain structure [48,49]. These findings suggested that
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SG might promote the drug absorption through transcellular pathway via perturbation of
mucosal membrane by SG and Sit-G.
   01eic acid has been used extensively as an enhancer in drug delivery from rectal
[50] and buccal [51] mucosa, and has been shown to alter membrane permeability by
increasing the motional freedom or fluidity of the membrane phospholipids [52].
Calcein leakage induced by oleic acid increased in a concentration-dependent manner
between O.2 mM and 1.0 mM of oleic acid (Figure 13A). Wang et al. [52] reported
that oleic acid at O.1 mM is capable of nonspecific disruption ofthe alveolar membrane.
However, our data suggested that oleic acid might cause little or no disruption but does
increase the fiuidity of the liposomal membrane, since it resulted in below 40 O/o calcein
leakage.
   As shown in Figure 13B and Table 7, calcein leakage induced by enhancers
significantly increased compared with control, and leakage at O.5 mM enhancers is as
following: oleic acid (5.7 O/o) Åq Sit (6.6 O/o) Åq SS (10.2 O/o) Åq SG (13.2 O/o) Åq Sit-G
(19.0 O/o). Table 8 shows calcein leakage from liposomes, and pharmacological
bioavailability following intranasal administration of insulin suspension [38] and
verapamil powder dosage form with enhancers. Insulin suspension, i.e., insulin-PBS
solution containing 1 O/o SG and Sit-G (18 mM), and 10 O/o oleic acid (354 mM) was
administered to the nasal cavity at a dose of 10 IUIkg in rabbits [38]. Both
pharmacological bioavailability of insulin and calcein leakage in O.5 mM enhancer were
increased in the order of oleic acid Åq SG Åq Sit-G (Table 8). These data suggested that
enhancers disturbed the transcellular pathway ofthe lipid layer in nasal mucosa.
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Figure 13. Effect of various enhancers on calcein leakage from liposomes with entrapped calcein in
incubation in methanol-1110 PBS (1:1) at 37 OC for 60 min
(A) OJeic acid, (B) X7: oleic acid, O: SS, []: Sit, A: SG, O: Sit-G
Hatched line indicates the solubility ofeach enhancer in a mixture solution ofmethanol-lflO PBS (1 :1).
Each value represents the mean Å} S.D. (n=3-6).
The total lipid concentration was 1.238 pmoYmL.
Table 8. Comparison between calcein leakage from liposomes with entrapped
calcein and bioavailability by oleic acid, SG and Sit-G
Enhancer (mM) Calcein leakage a) (o/,) F (O/o)Insulin b) Vera amilC)
Oleic acid
SG
Sit-G
ig•i{•g]]*** ,ii7iig']]*" gg`,'9',sg]*
Each value represents the mean Å} S.D. (n=3-6). *pÅq O05, *"pÅq O.O1, *""pÅqO.OO1
a)The enhancer concentration was O.5 mM and the incubation was at 37 OC for 60 min.
b)Pharmacological bioavailability (from O to 8 hr) of intranasally administered insulin-PBS solution (IO
IUfkg) containing 1.0 O/o SG and Sit-G, and 10 O/o oleic acid from Ando et. al. [ref. 38]
C)Bioavailability from O to infinity following intranasal administration of verapamil powder containing SG
or Sit-G at a dose ofO.75 mglkg.
d)No data.
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3-4. Change oflCa2'7i by Sit-G
   Paracellular absorption of drugs is restricted by tight junctions. It was reported
that the increase in [Ca2']i was related to the opening of tight junctions [33]. For
example, CIO as typical absorption enhancer caused the opening tight junctions via
increase in [Ca2']i, and contraction of actomyosin rings [33,53]. On the other hand,
ethylendiamine-tetraacetate (EDTA) is also known as an absorption enhancer, but its
enhancing mechanism is quite different from CIO since EDTA induced the opening of
tight junctions owing to the activation of protein kinase C by the chelation of
extracellular calcium ion [33]. Thus, it is the clue for the infiuence of absorption
enhancers on paracellular pathway to estimate the change in calcium ion inside or
outside cell. There are no binding sites with calcium ion on the structure of SG and
Sit-G and the solubility of these compounds in water is very low, suggesting that SG
and Sit-G could not induce the chelation with calcium ion in extracellular sources.
Moreover, the efficiency of Sit-G as an enhancer for insulin [38] and verapamil was
higher than that of SG. It was considered that the drug absorption was facilitated
through the nasal mucosae by SG as the same mechanism as by Sit-G. Therefore, the
effects on the paracellular pathway by Sit-G was determined by measuring the changes
in [Ca2']i.
   Figure14 shows the changes in [Ca2']i ofthe excised ofnasal mucosae in Ca2' free
D-PBS (A) and D-PBS containing 1.4 mM Ca2' (B) after the addition of Sit-G. The
addition of 1.4 mM Ca2' and ionomycin rapidly increased [Ca2']i after the treatment
with Sit-G, although the addition of Sit-G did not induced the [Ca2']i in Ca2' free
D-PBS (Figure 14A). On the other hand, Sit-G increased [Ca2']i in D-PBS (Figure
74B). These observations suggested that Sit-G did not directly increase [Ca2']i unlike
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   [Ca2']i
•9 DMso (A) da(]2 (B) Ionornycin
EIE
          Start lo 20 30 40 50 (min) start lo 20 3o (min)
 Figure 14. The effect of 50 pM Sit-G on intracellular calcium concentrations in the excised nasal
 mucosa from rabbits in Ca2' free D-PBS (A), and in D-PBS containing Ca2' (B) •
 The arrows indicate the time of addition of 1 O/o DMSO (2 mL), 200 pM Sit-G (50 pL), 200 mM
 CaCl, (50 ptL), and 26 pM ionomycin (4 mL).
 Ordinate axis represents the change of fluorescent intensity ratio of fura PE3 and this change
 corresponds to that ofthe intracellular calcium levels.
the effect of CIO [33], but the increase of [Ca2']i is a secondary factor accompanying
alteration of the nasal mucosae by Sit-G. Also, the ionomycin after the addition of
Sit-G did not affect the [Ca2']i.
    Oleic acid below O.05 mM increased [Ca2']i in alveolar cells only in the presence of
Ca2' due to the influx of Ca2' from extracellular sources [52], suggesting that the
increase of [Ca2']i is explained by influx of extracellular calcium ions via perturbation
ofthe nasal mucosal membrane by Sit-G. This fact was also explained by the results
of calcein leakage from liposomes. As mentioned above, Sit-G induced the
perturbation of liposomal membrane from the fact that Sit-G and SG increased the
calcein leakage from liposomes entrapped calcein compared with control, Sit and SS.
These data suggest that the mechanism of the increase in [Ca2']i by Sit-G is similar to
that of oleic acid. That is, Sit-G may increase the motional freedom of Iipids in the
mucosal membrane, and facilitated Ca2' influx from extracellular sources. Another
possibility is Sit-G may act as an ionophores and make holes as reverse micelles [53].
However, the detailed mechanism ofthe increase in [Ca2']i by Sit-G is not clear. Thus,
the influence of Sit-G on paracellular pathway was investigated, measuring the change
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in TEER and FD-4 permeability.
3-5. Change ofTEER and FD-4permeability by Sit and Sit-G
   Figure 15 shows the change in TEER and FD-4 permeability by the addition of
enhancers at 1 O/o wlv to donor side. Ussing chamber system is usefu1 to evaluate the
enhancing mechanism of enhancer because of monitoring the TEER and permeated
drug through mucosal membrane at the same time. Especially, this method is suitable
for evaluation ofenhancer on paracellular pathway. As mentioned above, C1O induced
the opening of tight junctions due to [Ca2"]i, resulting in increase of the drug
permeation via paracellular pathway accompanying with a decrease in TEER [32,53].
This result is consistent with the observation shown in Figure 15, since C10 caused the
increase in FD-4 permeation with decreasing TEER values compared with control.
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Figure 15. Effects of enhancers on TEER and FD-4 permeation through the excised nasal mucosa in rabbits
D: 1 O/o wlv Sit suspensions, O: 1 O/o wlv Sit-G suspensions
Each value represents the means Å} S. E. except for sodium caprate (n= 4).
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Table 9. Effects ofenhancers on TEER and FD-4 permeability in vitro
Enhancer
   T[EER a)
(O/o ofinitia1 value)
      b)Papp
x lo-6 cm
Ef c)
Control d)
1 O/o wlv C1O
1 O/o wlv Sit
1 o/, wlv Sir-G
i:!il,ZIO, ] *
101.8 Å} 1.3 ] "
II]•!•iO,1,i`,]*
2.86 Å} O.38
  1.0
** g13o Å} o.3 ]"
  2.9 Å} O.4
**
 Each value represents the mean Å} S.E. (n=4-6).
 a) TEER value at 120 min 1 initial value.
 b) Apparent permeation coefficient (Papp) was calculated from the following equation
   Papp = (dQldt)ICo
   where dQldt is the flux (pglcm2), and Co is the initial concentration ofFD-4 on the donor side
 c) Ef; enhancing factor in liquid dosage form == Papp enhancer 1 Papp control
 d) Control was Ringer's solution containing FD-4.
   As shown in Figure I5 and Table 9, Sit-G significantly increased Papp value
without change in TEER value. The increase in [Ca2']i is insufficient to affect the
actin-filaments; therefore, no change was seen in TEER. The results of [Ca2']i as well
as permeation study using Ussing chamber indicate that Sit-G has a little but not
bypassed action to the opening of tightjunctions. These observations suggested that
Sit-G contributes partly to the opening of tight junctions, but it mainly acts in the
transcellular pathway. This is also supported from FD-4 transport pathway observed
by a confocal Iaser microscopy. As shown in Figure 16, the intracellular fluorescent of
FD-4 was partly observed after FD-4 was applied together with Sit-G, although the
FD-4 has been reported to be mainly permeated via the paracellular pathway in the nasal
mucosae as well as Caco-2 cell. [54,55].
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Figure 16. 0bservation ofFD-4 fluorescence on horizontal and vertical cross-sections
after permeation study of FD-4 with 1 O/o w!v Sit-G suspensions for 2 hr across rabbit
nasal epithelium by confocal laser scanning microscope
Series of3 horizontal cross-sections from O (horizontal) to -12 pm, taken with steps of
4 pm thickness. Top is apical, bottom is basolateral.
   On the other hand, Sit, aglycon of Sit-G, significantly increased Papp values
compared with control (Table 9) and its effect on TEER was different from Sit-G,
showing decrease in TEER by 10 min after application of Sit. This finding
corresponded well with the observation that Tmax value of FD-4 powder dosage form
with Sit in vivo was smaller than that with Sit-G. In FD-4 powder dosage form, Sit
enhanced the permeation of FD-4 (I7igure 11A), but did not affect FD-4 uptake into the
nasal mucosa compared with control (Figure 11B). It has been reported that Sit can
substitute for cholesterol in HepG-2 cells [56] and keratinocytes, and it causes transitory
perturbation of membranes [57]. In the present study the uptake of Sit in the nasal
mucosae increased compared with that of Sit-G (Figure 11C), but the amount of
remaining cholesterol was not changed (data not shown). These findings suggested
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that Sit did not substitute for cholesterol in the nasal mucosa and Sit was rapidly taken
up into nasal mucosae after administration ofthe powder dosage form.
  The relationship between Papp and AUC values of FD-4 liquid dosage forrns, and
that between ]PaLpp and AUCTEER values except for Sit-G were linear (r =O.960, r==O.998),
respectively (.Figure 17). The increase of Papp value with Sit and CIO may be
involved with a decrease in TEER except for Sit-G. In general, hydrophilic drug
permeation through the intracellular space is dependent on the TEER value in the
mucosal membrane, which is related to the integrity on the junctional complex. This
was supported by the good correlation with a decrease in TEER, and increase of AUC,
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enhancement factor (ELD: i.e., the ratio ofF value with enhancer to that with control, vs.
Papp values (Figure 17 and Table 9). Sit may loosen the tightjunctions, and increase
the drug permeation via the paracellular pathway similarly to CIO. Thus the
enhancement mechanism of Sit-G is different from that of Sit.
   The aglycon derivative glycyrrhenic acid was enzymatically produced from
glycyrrhizin, and increased drug permeation with a decrease in the TEER value.
Thereby, glycyrrhenic acid can enhance drug absorption via the paracellular pathway in
vivo, however glycyrrhizin did not [58]. The mechanism of enhancement by Sit
appears to be similar to that of glycyrrhenic acid, but no such exchange from Sit-G to
Sit in nasal mucosae was detected and Sit-G itself showed stronger
absorption-enhancing effect than Sit both in vivo and in vitro. Further, the intracellular
calcium levels were reported to be increased by the application of Sit [59]. These
findings suggest that the decrease in TEER value by Sit is accompanied by an increase
in [Ca2']i, causing the loosening oftightjunctions.
     The enhancers can be classified into two types based on differences in their
mechanism of transport, i.e., paracellular and transcellular types. CIO and EDTA
enhanced the drug permeation via paracellular pathway associated with marked
decrease in TEER. Palmitoylcamitine facilitate drug absorption by membrane
perturbation effects with a slight increase in the intracellular calcium level (transcellular
pathway) [32,37]. This action was observed by the introduction of SG containing
Sit-G as the main component into liposomes, which markedly increased the membrane
fiuidity at 37 OC as determined by measuring electron spin resonance [60]. These
findings suggested that the mechanism of action of Sit-G was similar to that of
palmitoylcarnitine rather than C1O or EDTA.
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     The transcellular type enhancers such as Sit-G facilitate drug absorption through
the inside of cells; therefore, usefu1 as topical application for gene therapy to increase
the introduction of genes into the mucosal cells without initation of the mucosae.
47
  4. Conclusions
       Sit-G increased bioavailability of verapamil, FD-4 and insulin after intranasal
  administration at the powder dosage form. The enhancing action of Sit-G was higher
  than that of Sit. As the results of calcein leakage from liposomes as the model of
  biomembrane after incubation with enhancers, calcein leakage induced by enhancers
  was in the order of oleic acid Åq SG Åq Sit-G. This order was same as that of the
  enhancement action of bioavailability of verapamil and insulin. Moreover, Sit-G
  increased [Ca2']i in the medium containing Ca2', but did not in Ca2' free medium.
  With respect to the increase of [Ca2']i, it was considered that the Ca2' influx was
  induced by Sit-G due to the perturbation of mucosal membrane, or Sit-G acted as
  ionophores and made holes as reverse micelles on the mucosal membrane.
       However, the increase of [Ca2']i dose not relate to the opening of tight junctions
  since Sit-G increases the FD-4 permeability through the excised rabbit nasal mucosa
  without decrease of TEER. These findings suggested that Sit-G might enhance the
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Figure 18. Absorption enhancing mechanism ofSit-G and Sit after intranasal administration of
dosage forms with Sit-G (A) and Sit (B)
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drug absorption via the transcellular pathway due to perturbation of mucosal membrane
(Figure 18), and this is also supported by the observation ofFD-4 transport pathway by
confocal laser microscopy, which showed that the fluorescence of FD-4 was widely
distributed except in goblet cells. On the other hand, Sit contributes mainly the
opening of tight junctions (Figure 18) as an increase in FD-4 permeation along with a
decrease in TEER was seen by the application ofthis compound.
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Ch apter III
Effect ofNanoparticle Based on /iSitosterot /iLD-Gtucoside and
ICLSitosterot on IntranasatAbsorption ofFITC-Dextran 4,400
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1. Introduction
    As described in Chapter ll, Sit and Sit-G enhanced effectively the drug absorption
across the nasal mucosa, and the enhancement mechanism of these enhancers was
elucidated by various in vitro experiments. One of the shortcomings of these
enhancers is a poor dispersibility in water due to their high hydrophobicity. This
restricts the administered dosage form, resulting in a limitation of the enhancing ability.
In the dispersions of Sit and Sit-G powders (Åq 75 pm), most of them floated at the
surface of water. To solve the poor dispersibility of Sit and Sit-G in water, the NP
composed of Sit and Sit-G were developed (Sit and Sit-G NP). The aim in Chapter III
was to evaluate the enhancing effect of Sit and Sit-G NP in vivo and in vitro, and to
elucidate the mechanism ofenhancement in comparison with Sit and Sit-G suspensions.
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2. Experimental Section
2-1. Materials
    Sit, Sit-G, FD-4 and CIO were the same ones in Chapter II. Phloridzin (PHZ),
was purchased from Sigma Chemical (St. Louis, MO). Sodium oleate was purchased
from Tokyo Kasei Kogyo (Tokyo, Japan). All other chemicals used were ofanalytical
reagent grade.
2-2. Preparation ofdosageform
   For preparation of suspension, the powder of enhancers sieved with 200 mesh (75
pm, SP) was dispersed into PBS and prepared by sonication (SP suspension). Sit and
Sit-G NP was prepared by the modified ethanol injection method [11]. Briefly, 10 mg
Sit or Sit-G, and 50 mg sodium oleate were dissolved in hot ethanol 60 OC, and then 20
mL of PBS was added. Ethanol was removed from the resultant O.05 O/o wlv NP
suspension. The size and polydispersity index of prepared NP was about 80 iim and
less than O.25, respectively (Figure 19). FD-4 was dissolved in the SP and NP to the
Figure 19. 0bservation of Sit-G nanoparticles
by freeze fracture (magnification x 1OO,OOO)
                    52
required concentration, respectively.
2-3. Animal experiment
    Aliquot of 50 pL each liquid dosage form were administered via nostril of
Japanese white rabbits (about 2 kg, Sankyo Laboratory, Japan) restrained in the supine
position for 5 min at a dose of 1 mgfkg FD-4. At each time point, the blood samples
were taken from ear vein until 8 hr Plasma concentration, F value and absorption
constant rate (Ka) values were determined by the method described in Chapter ll.
AUC ofFD-4 from time O to 8 hr was estimated from the sum of successive trapezoids
between each data point.
2-4. Measurement ofFD-4 and TEER in the Ussing chamber
    The experimental methods were described in Chapter II. Briefly, The excised
nasal mucosa was mounted onto a tissue adapter in an Ussing chamber (CEZ-9100,
Nihon Kohden, Tokyo, Japan). Each chamber was fi11ed with Ringer's solution.
Temperature was kept constant at 37 OC by a waterjacket. After preincubation for 1 hr,
O.05 O/o w/v ClO solution, and Sit and Sit-G SP, and Sit and Sit-G NP was added to the
donor side. For inhibition study of glucose/Na' cotransporter using PHZ, PHZ was
added to the donor side. Samples and TEER were taken from receiver side, and
measured at every 1O min up to 120 min.
2-5. Data analysis
    The data analysis was carried out by the method mentioned in Chapter L
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3. Results and Discussion
3-1. Effects ofSP and NP on intranasal absorption ofFD-4
    From the gel-filtration of FD-4 and NP (NP dosage from), FD-4 was not housed in
NP (data not shown). Figure 20 shows the plasma concentration profiles of FD-4
following intranasal administration of Sit and Sit-G SP and NP at a dose of 1 mg
FD-41kg in rabbits. Sodium oleate at O.25 O/o w!v was control as the NP dosage form.
CIO was used as the active control since it is widely used as the absorption enhancer.
Table 10 summarized the bioavailability, Ka, and Papp values. Sodium oleate did not
affect FD-4 absorption through nasal mucosa since no significant difference on the
bioavailability ofFD-4 was observed between sodium oleate and PBS control (P År O.05)
This finding suggested that enhancement of FD-4 absorption by both NP was not due to
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 Figure 20. Plasma concentration profile of FD-4
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 (A) SP suspension A: PBS, O: O.050/o (wlv) C 10,
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sodium oleate but to Sit or Sit-G. Sit and Sit-G NP showed significantly 3.8- and
5.1-fold higher bioavailability than PBS control, and 1.8- and 1.7-fold higher than Sit
and Sit-G SP, respectively. Sit-G enhanced the FD-4 absorption compared with Sit in
NP and SP, respectively. Ka values of Sit-G NP significantly increased compared with
Sit (Table 10). Thus, NP was more effective form than SP, and Sit-G NP was more
effective than that of Sit NP.
Table 1O. Bioavailability and absorption rate constant (Ka) value ofFD-4 following
intranasal administration of FD-4 with each liquid dosage form at a dose of 1 mg
FD-4!kg in rabbits, and permeability coefficient (Papp) of FD--4 according to
permeation study in vitro at O.050/o wlv enhancer
Enhancer
F a)
(o/o)
Ka
(hr-i)
      b)Papp
   -6
     cm)(x 1O
Sohaion
  PBS
  Sodiurn oelate
  CIO
Suspension
  sit
  Sit-G
Nanoparticle
  sit
  Sit-G
  Sit--G + PHZ
4.0 Å} O.8
4.6Å}1.0
7.3 Å} O.7
 8.7Å} 1.1
12.0 Å} O.6
I5.3 Å} 2.2
20.2 Å} O.9
   - c)
]*
]** *
1.11Å}O.09
1.01 Å} O.12
3.63 Å} O.46
1.09 Å} O. 13
1.36 Å} O.21
1.82 Å} O.47
         ]**
6.18 Å} O.76
   - c)
**
l.20 Å} O.35
   - c)
5.18
]81;814,2]*
1.23 Å} O.28
         ]*
2.84 Å} O.87
3.18Å} 1.20
Each value in intranasal administration and permeation study is represented as the mean Å} S.E. and S.D.,
respectively. (n;4)
*p Åq O.05, **p Åq O.Ol
a) F (from O to 8 hr)
b) Papp = (dQldt)!(C, x A)
where dQldt is the flux (mg!cm2), Co is the initial concentration ofFD-4 in donor side and A is the surface area.
c) Not detemined
3-2. Jnfluence ofSP and NP on TEER and FD-4permeation
Sit-G NP, Sit-G and Sit SP, and CIO solution increased significantly Papp values
compared with control, while Sit-G NP and Sit SP significantly decreased TEER by
55
70 O/o at 1O min, returning to 90 O/o by 30 min, and kept a significant decrease similar to
CIO, respectively (Figure 21 and Table 10). The decrease ofTEER induced by Sit-G
NP was diminished by the addition of the specific substrate of the glucoselNa'
cotransporter PHZ at 1 mM [61] to the donor side (Figure 21), but no change of Papp
values was seen (Table 70). Sit-G NP may have affmity to the glucoselNa'
cotransporter, resulting in a decrease of TEER, but such phenomenon was not seen in
the case of Sit-G SP. The glucose residue of Sit-G is recognized more readily by the
glucosefNa' cotransporter in the form ofNP than in SP.
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Figure 21. Effects ofenhancers on TEER and FD-4 permeation through the excised nasal
mucosa in rabbits by the addition ofenhancers
A: control, ÅqÅr: O.05 O/o wlv CIO, O: O.05 O/e wlv Sit SP, O: O.05 O/o wlv Sit-G SP
-: O.050/o wlv Sit NP, e: O.050/o wlv Sit-G NP, ": O.050/o wlv Sjt-G NP + 1 mM PHZ
Each value represents the means Å} S.E. except for sodium caprate (n=4).
Data for sodium caprate represent means (n=2).
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4. Conclusions
    Co-administration of Sit or Sit-G NP with FD-4 in nasal mucosa significantly
increased bioavailability. Sit-G NP is readily recognized by the glucoselNa'
cotransporter unlike Sit-G SP. Sit and Sit-G NP might interact with nasal mucosa
compared with their SP due to the small particle size and providing the uniformly
dispersion in nasal fluid. NP incorporated Sit and Sit-G are potential dosage forms as
a nasal delivery for a hydrophilic and high molecular weight drug such as FD-4.
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SUMMARY
   The nasal absorption has received an increased attention especially in improving the
delivery of peptide drugs. In this thesis, I have used bioadhesive polymers as drug
carriers, absorption enhancers and nanoparticle dosage forms to a control of drug
release and to increase bioavailabilities for nasal drug delivery. Drug release from the
drug-loaded polymers exhibited classical Fickian kinetics after an initial burst, and the
system was evaluated using nasal rabbits to confirm whether these polymer-gels could
effectively deliver the drug in physiological conditions, such as nasal mucosa.
As described in Chapter ll and III, Sit-G and Sit significantly facilitated the absorption
of verapamil and FD-4 as well as insulin following intranasal administration of the
powder, liquid and nanoparticle dosage forms. It was evident that Sit-G exhibited the
stronger absorption activity (Table 11). Absorption enhancers are classified into two
groups; the paracellular and transcellular types. Most of enhancers are involved in the
former type, which looses the tight junctions via various mechanisms, i.e., i) increase in
the intracellular calcium levels, ii) depletion ofcalcium ion in tightjunctions. Results
of mechanistic study of Sit-G revealed that the behavior of transepithelial resistance
(TEER) was not consistent with the observation of paracellular type enhancer such as
sodium caprate, EDTA and chitosan. Sit-G increased the permeability of drug across
the excised nasal mucosa without a decrease in TEER value, although Sit increased it
accompanying with a decrease in TEER. The decrease of TEER value means the
increase of ion transport from the mucosal to serosal side, close relating to the opening
of tight junctions. These findings suggested that Sit-G did not act in the paracellular
pathway. To estimate influence of Sit-G on mucosal membrane, liposomes entrapped
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Table 1 1. Bioavailability of various dosage form of insulin, verapamil and FD-4
formulae with enhancers following intranasal administration in rabbits
Drug Dose Formulation Enhancer Fa) o/o
Insulin 1O IUlkg Suspension
   1O O/o wlv oleic acid
b)
   1 o/, wlv SG
   1 O/owlvSit-G
 3.2 Å} 1.4
 6.7 Å} 1.4
11.3 Å} 1.6
Verapaml O.75 irg!kg       c)Powder
Lactose (control)
SG
Sir-G
39.8 Å} 3.4
60.4 Å} 3.5
90.7 Å} 9.8
Powder d)
Lactose (control)
Sit
Sit-G
4.1 Å} 1.1
6.9 Å} O.4
8.3 Å} 1.0
FD-4 1 mgAcg
Solution
PBS (cotnrol)
o.os o/o wlv c1o
1.0 O/owlvCIO
2.6 Å} O.4
5.6 Å} O.3
8.2 Å} 2.9
Suspension
  SP b) o.os e/, wlv sit
o.os o/o wlv sir-G
5.8 Å} O.9
8.9 Å} O.4
Np e) O.05 O/o wlv Sit
o.os O/o wlv Sit--G
 9.2 Å} O.8
11.7 Å} O.7
 a) F from O to 8 hr for insulin, F from O to infinity for verapamil and F from O to 3 hr for FD-4.
 b) Panicles are less than 75 pm.
 c) verapamil:enhancers = 1:3 weight
 d) FD-4:enhancer = l :2 vveight
 e) The size ofnanopanicle is about 80 nm.
calcein were incubated with enhancers. Sit-G induced the calcein leakage, but Sit did
not, suggesting that Sit-G perturbs mucosal membranes, thereby, drug absorption
increased via transcellular pathway. On the contrary, Sit facilitates drug absorption via
paracellular pathway.
   While Sit-G and Sit are useful as an enhancer, they are scarcely soluble in water.
In order to solve this drawback, preparation of nanoparticle based on Sit and Sit-G was
investigated. The success ofthe preparation ofnanoparticles resulted in the preferable
dosage form for nasal delivery with an enhancer of Sit or Sit-G. Sit and Sit-G
nanoparticles significantly enhanced FD-4 absorption following an intranasal
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administration of FD•-4. Especially, Sit-G nanoparticle showed the greatest activity
arnong other dosage forms.
   Modulation of the gel swelling and mucoadhesiveness may prove usefulness in the
controlled release of drug from pH-sensitive and adhesive polymer at the surface ofthe
nasai mucosa in vivo. For the poor absorbable drugs across nasal mucosae, Sit-G is a
usefu1 transcellular type enhancer in nasal absorption of drugs. Furthermore, Sit-G
nanoparticles may be applicable as an enhancer in the intestinal, or other mucosal
delivery.
   In conclusion, nasal administration of drugs, especially peptides, along with
bioadhesive polymers or nanoparticle dosage forms in combination with nontoxic
enhancer, i.e., Sit-G provides a promising method as an alternative for the injection.
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